Foreign pharmaceutical representatives listening to a presentation at the RudaCure booth.
RudaCure set up a booth in the Rising Pavilion at 2025 Bio-Korea, recommended by KIT, and introduced the current status of drug development for TRPV1-related diseases.
Chinese and American companies expressed strong interest in the overseas rights for RCI001, which is currently in clinical trials. For the veterinary pain treatment currently under development, discussions on development stages and market were conducted through partnering meetings with a multinational veterinary pharmaceutical developer headquartered in the United States.
The non-narcotic analgesic development project attracted interest from investors and major domestic pharmaceutical companies, and RudaCure's booth was bustling with visitors throughout the event period.
[Correction notice · 15 September 2026] The mechanism of action described for RCI002 (RC-0165) in this article reflects the company's position at the time of publication. Naloxone was subsequently shown to fully block analgesia in the MIA osteoarthritis model, and the company has corrected the description: RCI002 is not a TRPV1-MOR dual-target non-opioid analgesic but a mu-opioid receptor (MOR) agonist administered by intra-articular injection. The current description is on the pipeline page.